Osteoarthritis (OA) is the most common form of arthritis, and is a public health problem throughout the world. It remains the major cause of disability in the elderly, affecting about 60% of men and 70% of women above the age of 65. Even though there are many medicines for treatment of OA throughout the world, therapeutic potential of traditional Korean medicine (TKM) is not well known. Here we discussed the therapeutic potential of BaekJeol-tang (BJT, a prescription of TKM). Celecoxib is approved in one or more countries worldwide for the relief of the signs and symptoms of OA, rheumatoid arthritis, and juvenile rheumatoid arthritis. Although celecoxib inhibited mRNA expression of matrix metalloproteinase (MMP)-3 and increased mRNA expression of tissue inhibitors of metalloproteinase (TIMP)-1, celecoxib did not significantly inhibit IL-$1{alpha}$-induced release of glycosaminoglycan (GAG) and only slightly reduced type II collagen. On the other hand, BJT significantly inhibited the release of GAG and type II collagen as well as regulated the mRNA expression of MMP-3 and TIMP-1. Through this article, we have tried to provide some therapeutic potential of BJT in arthritis.